| Author(s) | Khalkhali-Ellis Z; Hendrix MJC
|
|---|
| Title | Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells
|
|---|
| Source | AMERICAN JOURNAL OF PATHOLOGY 162 (5): 1411-1417
|
|---|
| Date | 2003 MAY
|
|---|
| Type | Journal : Article
|
|---|
| LCR: 5 NCR: 27 LCS: 1 GCS: 4
| | Comment |
|
|---|
| Address | Univ Iowa, Dept Anat & Cell Biol, Roy J & Lucile A Carver Coll Med, Holden Comprenens Canc Ctr,Carver Coll Med, Iowa City, IA 52242 USA.
|
|---|
| Reprint | Khalkhali-Ellis, Z, Univ Iowa, Dept Anat & Cell Biol, Roy J & Lucile A
Carver Coll Med, Holden Comprenens Canc Ctr,Carver Coll Med, BSB 1-100,
Iowa City, IA 52242 USA.
|
|---|
| Abstract | In this study, we examined the unique relationship of maspin, a serine protease inhibitor (serpin), that plays a critical role in mammary gland development and is silenced during breast cancer progression, and nitric oxide (NO), a multifaceted water and lipid soluble free radical. The hypothesis tested was that there is a correlation between endothelial nitric oxide synthase and maspin in MCF-7 cells and that NO is capable of regulating maspin expression. An experimental system was developed in which cellular levels of NO in normal human mammary epithelial cells and the breast cancer cell line MCF-7 could be altered using NO modulators. The effect(s) of NO modulators on maspin was measured using reverse transcriptase-polymerase chain reaction and Western blot analysis of subcellular fractions of both cell types. The data revealed that NO Induced maspin expression in MCF-7 cells, and the induced maspin resulted in diminished cell motility and invasion, concomitant with an increase in the apoptotic index. This novel finding provides new information regarding the molecular role of maspin in regulating mammary epithelial growth, remodeling, tumor progression, and the metastatic process. More significantly, these findings could have a potential impact on future therapeutic intervention strategies for breast cancer. Targeted delivery of NO within the tumor microenvironment could provide a feasible noninvasive approach for effective treatment.
|
|---|
| CR |
AMBS S, 1997, FASEB J, V11, P443
BRUNE B, 1998, EUR J PHARMACOL, V351, P261
CHENG AW, 2001, J BIOL CHEM, V276, P43320
DIMMELER S, 1997, NITRIC OXIDE-BIOL CH, V1, P275
DONG ZY, 1994, CANCER RES, V54, P789
DUENASGONZALEZ A, 1997, MODERN PATHOL, V10, P645
KIM PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421
LE WD, 1995, BRAIN RES, V686, P49
MAASS N, 2001, CLIN CANCER RES, V7, P812
MAASS N, 2002, J PATHOL, V197, P273
MARTIN JHJ, 1999, CANCER LETT, V144, P65
MORTENSEN K, 1999, J BIOL CHEM, V274, P37679
NATHAN C, 1992, FASEB J, V6, P3051
NICOTERA P, 1997, TRENDS PHARMACOL SCI, V18, P189
ODEROMARAH VA, 2002, BIOCHEM BIOPH RES CO, V295, P800
OOBOSHI H, 1997, AM J PHYSIOL, V273, P265
REIS JS, 2002, J PATHOL, V197, P272
REVENEAU S, 1999, LAB INVEST, V79, P1215
SAGER R, 1996, CURR TOP MICROBIOL I, V213, P51
SCHMIDT HHHW, 1994, CELL, V78, P919
SEFTOR REB, 1998, CANCER RES, V58, P5681
SEFTOR REB, 2002, LANDES BIOSCI, P84
SHENG S, 1996, P NATL ACAD SCI USA, V93, P11669
STERNLICHT MD, 1997, CLIN CANCER RES, V3, P1949
UMANSKY V, 2000, INT J ONCOL, V16, P109
ZEILLINGER R, 1996, BREAST CANCER RES TR, V40, P205
ZOU ZQ, 1994, SCIENCE, V263, P526
|
|---|
|